EDAP Edap Tms S.A. ADS

EDAP TMS SA to Announce First Quarter 2020 Financial Results on May 13, 2020

EDAP TMS SA to Announce First Quarter 2020 Financial Results on May 13, 2020

Company to host conference call and webcast on Thursday, May 14 at 8:30 am EDT

LYON, France, May 6, 2020 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the first quarter ended March 31, 2020 after the markets close on Wednesday, May 13, 2020.

An accompanying conference call and webcast will be conducted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, and François Dietsch, Chief Financial Officer. The call will be held at 8:30am EDT on Thursday, May 14, 2020. Please refer to the information below for conference call dial-in information and webcast registration.

Conference Call & Webcast

Thursday, May 14th @ 8:30am Eastern Time

Domestic:                    877-451-6152

International:              201-389-0879

Passcode:                    13703225

Webcast:                    

About EDAP TMS SA

A recognized leader in the global therapeutic ultrasound market for almost 40 years, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for urology using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in 2013 in Europe and in 2018 in the US as the answer to all requirements for ideal prostate tissue ablation as a complement to the existing FDA-cleared Ablatherm® Robotic HIFU and Ablatherm® Fusion. As a pioneer and key player in the field of extracorporeal shock wave lithotripsy (ESWL), EDAP TMS exclusively utilizes the latest generation of shock wave source in its Sonolith® range of ESWL systems. For more information on the Company, please visit -tms.com, and us.hifu-prostate.com.

CONTACTS:

Blandine Confort

Investor Relations / Legal Affairs

EDAP TMS SA

50

Investor Contact

Jeremy Feffer

LifeSci Advisors, LLC

212-915-2568



 

 

EN
06/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Edap Tms S.A. ADS

 PRESS RELEASE

Focal One® Prostate Cancer Awareness Month Campaign Shines Spotlight o...

Focal One® Prostate Cancer Awareness Month Campaign Shines Spotlight on Robotic HIFU Treatment Option Focal One® Prostate Cancer Awareness Month Campaign Shines Spotlight on Robotic HIFU Treatment Option Focal One Robotic HIFU Patient Story Featured on Health Uncensored with Dr. Drew on Lifetime Network  AUSTIN, Texas – September 30, 2025 – EDAP TMS SA (Nasdaq: EDAP), a global leader in robotic energy-based therapies, announced that its non-invasive, nonsurgical treatment option, Focal One Robotic HIFU, was featured on national television on Friday, September 26, reaching millions of view...

 PRESS RELEASE

Focal One® HIFU Receives Prestigious Innovation Award

Focal One® HIFU Receives Prestigious Innovation Award           Focal One® HIFU Receives Prestigious Innovation Award AUSTIN, Texas, September 16, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced today that the company has been honored with the 2025 Industry Award for Innovations in Endourological Instrumentation by the Endourological Society in recognition of its groundbreaking work with the Focal One High-Intensity Focused Ultrasound (HIFU) platform. Focal One is the first Focal Therapy technology to receive this distinguished award. The...

 PRESS RELEASE

EDAP Receives HIFU Reimbursement for Prostate Cancer in France

EDAP Receives HIFU Reimbursement for Prostate Cancer in France Focal One Robotic HIFU procedure now covered under France’s national universal health systemReimbursement milestone allows increased patient access to Focal One Robotic HIFU AUSTIN, Texas, September 8, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced today that the French Ministry of Health has awarded reimbursement for High Intensity Focused Ultrasound (HIFU) procedure for the treatment of prostate cancer in France. Reimbursement in France will specifically cover use of the Foca...

 PRESS RELEASE

EDAP Reports Strong Second Quarter 2025 HIFU Results

EDAP Reports Strong Second Quarter 2025 HIFU Results +140% Focal One® Net Placement Growth Year over Year+76.8% HIFU Revenue Growth Year over Year 36 million Euro Credit Facility Letter of Intent Executed with European Investment Bank (EIB) to further accelerate HIFU Growth and Strategic Expansion Company raises 2025 HIFU Year over Year Revenue Growth Guidance range to 26% to 34%, up from the prior range of 16% to 25%  Company to Host Conference Call and Webcast Today, August 28th, at 8:30 a.m. EDT  AUSTIN, Texas, August 28, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic ...

 PRESS RELEASE

EDAP Announces Letter of Intent for 36 Million Euro Credit Facility to...

EDAP Announces Letter of Intent for 36 Million Euro Credit Facility to Accelerate Growth and Strategic Expansion Funding to Support Continued Growth of Focal One® Robotic HIFU AUSTIN, Texas, August 26, 2025 - EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced execution of a letter of intent for EUR 36 million credit facility with the European Investment Bank (EIB). Proceeds from this financing will support the continued expansion of Focal One® Robotic HIFU in Focal Therapy, the fastest-growing treatment category for ea...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch